M
Matija Tomšič
Researcher at University of Ljubljana
Publications - 196
Citations - 3973
Matija Tomšič is an academic researcher from University of Ljubljana. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 28, co-authored 163 publications receiving 3285 citations. Previous affiliations of Matija Tomšič include Academy of Sciences of the Czech Republic & Ljubljana University Medical Centre.
Papers
More filters
Journal ArticleDOI
Human mesenchymal stromal cells from different tissues exhibit unique responses to different inflammatory stimuli.
Blaž Burja,Blaž Burja,Ariana Barlič,Andreja Erman,Katjuša Mrak-Poljšak,Matija Tomšič,Matija Tomšič,Snezna Sodin-Semrl,Snezna Sodin-Semrl,Katja Lakota,Katja Lakota +10 more
TL;DR: This study highlights origin-specific MSC profile differences and emphasizes a heterogenic response of different MSC to inflammatory stimuli, and suggests that MSC-CM could contribute to decreased mitotic potential and increased apoptotic rate in lung fibroblasts.
Journal ArticleDOI
Exploring the structural properties of simple aldehydes: a Monte Carlo and small-angle X-ray scattering study.
TL;DR: The structure of simple linear alkanals from propanal to nonanal was studied utilizing configurational bias Monte Carlo simulations of the aldehydes modeled according to the transferable potential for phase equilibria-united atom force field and was compared to experimental small-angle X-ray scattering results.
Journal ArticleDOI
Soluble Aggregates in Aqueous Solutions of Polyion–Surfactant Ion Complex Salts and a Nonionic Surfactant
TL;DR: It was found that mixed aggregates of polyacrylate, C16TA(+) ions, and C12E8, with almost constant stoichiometry, coexist with free micelles of C 12E8 at all investigated mixing ratios.
Journal ArticleDOI
Stroke and antiphospholipid syndrome-antiphospholipid antibodies are a risk factor for an ischemic cerebrovascular event.
N. Gašperšič,Marjan Zaletel,Jan Kobal,Polona Žigon,Saša Čučnik,Saša Čučnik,Snežna Sodin Šemrl,Snežna Sodin Šemrl,Matija Tomšič,Matija Tomšič,A. Ambrožič +10 more
TL;DR: Investigating whether the persistent presence of antiphospholipid antibodies represented a risk factor for a CVE, and focusing on the efficacy of the selected treatment strategy in the first year after the CVE, found antiplatelet therapy seemed to be sufficient in secondary CVE thromboprophylaxis in most APS patients.